tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Biotech'

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Written by Ι Stock Market Media — May 18, 2017

Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...

Read More →
0

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

Written by Ι Stock Market Media — May 20, 2015

PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science – bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting it into the hands of insulin-dependent patients around the world. These experts have become known collectively as the “International Diabetes Consortium,” and if PharmaCyte is to be successful, it will ...

Read More →
0

Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs

Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs

Written by Ι Stock Market Media Group Staff — October 29, 2014

New York, NY – Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world – the treatment of pain.

In addition to significantly strengthening the ...

Read More →
0

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Written by ι Stock Market Media Group Staff — October 3, 2013

Plandaí Biotechnology, Inc. (OTCQB: PLPL) has several clinical trials already underway, and a host of others scheduled to commence in the company months as the company feverishly prepares products for market in its transition from solely a research and development firm to a biotech with products in the marketplace.  Plandaí has stated its goal is to have most of the trials it has commissioned completed by the end of March 2014 ...

Read More →
0

Nuvilex, Inc.’s Marijuana Research into Cannabidiol Could Lead to Many Successes

Nuvilex, Inc.’s Marijuana Research into Cannabidiol Could Lead to Many Successes

Written by ι Stock Market Media Group Staff — October 3, 2013

Nuvilex, Inc. (OTCQB: NVLX) formed its subsidiary, Medical Marijuana Sciences, Inc., to study the medical applications of marijuana, and more specifically, it has chosen to focus its initial research on utilizing cannabidiol, or CBD, one of the compounds found in Cannabis, as the basis for developing treatments for serious and deadly forms of cancer.  The company wants to use its expertise, current research and its success in the biotechnology sector ...

Read More →
0

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

September 23, 2013

Stock Market Media Group, a research and content development investor relations firm, has released its 3rd Quarter report and issued a Speculative Buy Rating on Plandaí Biotechnology, Inc. (OTCQB: PLPL).  The report: Plandaí Biotechnology, Inc. – From R&D to Market, is the first in a series of reports that will follow Plandaí as it transitions from a biotech solely engaged in research and development to a company launching products into the marketplace.

Read the Plandaí Report at www.stockmarketmediagroup.com/reports.

In ...

Read More →
0
Page 1 of 2 12
ContactUs.com